CYAD — Celyad Oncology SA Share News
0.000.00%
Last trade - 00:00- €9.93m
- €9.80m
- €0.02m
Celyad SA: Rises after CAR-T therapy shows promise in treating bowel cancer
Brief: Celyad Provides Update On Allogeneic CAR-T Franchise
Brief: Celyad Q1 Treasury Position At 33.8 Million Euros
Brief: Celyad To Present Update From Cyad-101 For Advanced Colorectal Cancer, Next-Generation SHRNA Platform
Brief: Celyad Reports Full Year 2019 Financial Results And Provides Business Update
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:29 AM
Brief: Celyad Appoints Stephen Rubino As Chief Business Officer
Brief: Celyad Announces Good Results For CYAD-02 In CYCLE-1 Trial
Brief: Celyad Says Preliminary Data For Cycle-1 Trial Anticipated During Second Half 2020
Celyad SA: Rises on non-dilutive funding of 2.5 mln euros
Brief: Celyad Receives Additional 2.5 Million Euros In Non-Dilutive Funding
Brief: Celyad CEO Steps Down, Filippo Petti Nominated For Role
Celyad SA: Up on funding from Belgian regional government
Brief: Celyad Receives €8.5 Million Funding By The Walloon Region
Brief: Celyad Announces Q3 Financial Results And Recent Business Highlights
Brief: Celyad End-Sept Cash Position At 44.6 Million Euros
Brief: Celyad Announces Key Upcoming Milestones
Brief: Celyad Highlights Safety And Clinical Activity Of CYAD-101
Brief: Celyad To Present Update On MCRC Clinical Program At 2019 SITC Annual Meeting